Filing Details
- Accession Number:
- 0001209191-21-004749
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-21 19:08:54
- Reporting Period:
- 2021-01-19
- Accepted Time:
- 2021-01-21 19:08:54
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1434316 | Fate Therapeutics Inc | FATE | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1655472 | Cindy Tahl | C/O Fate Therapeutics, Inc.; 3535 General Atomics Court #200 San Diego CA 92121 | General Counsel And Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-01-19 | 35,000 | $2.90 | 125,035 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-01-19 | 15,835 | $114.11 | 109,200 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-01-19 | 14,944 | $115.09 | 94,256 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-01-19 | 4,021 | $115.97 | 90,235 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-01-19 | 200 | $117.07 | 90,035 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2021-01-19 | 35,000 | $0.00 | 35,000 | $2.90 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 28,149 | 2026-01-07 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.
- Represents the weighted average sale price of the shares sold ranging from $113.56 to $114.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
- Represents the weighted average sale price of the shares sold ranging from $114.60 to $115.5350 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
- Represents the weighted average sale price of the shares sold ranging from $115.6382 to $116.47 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
- Represents the weighted average sale price of the shares sold ranging from $117.04 to $117.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
- This option is fully vested.
- Not applicable.
Billionaire Hedge Funds
